Our Pipeline

Advancing a multi-asset pipeline of high-impact therapeutic solutions

Our pipeline is comprised of innovative therapeutic product candidates we believe have the potential
for value creation using our partnership-enabled business model

wait wait

Our flagship product candidates, AVIM Therapy and Virtue SAB, exemplify key criteria that characterize innovations optimized for strategic partnerships:

Icon

Target mature therapeutic
device markets with significant
unmet needs.

Icon

Provide high-impact
procedure-based solutions
with rapid adoption potential.

Icon

Offer strategic and financial
benefits to a commercial
partner and Orchestra BioMed.

* Plan to leverage existing coronary in-stent restenosis (ISR) data to support potential Pivotal Study; Virtue SAB has received Breakthrough Device Designation for:

1. The balloon dilation of the stenotic portion (up to 26 mm in length) of a stented coronary artery that is 2.25 to 4.0 mm in diameter, for the purpose of improving lumen diameter.

2. The balloon dilation of the de novo stenotic portion (up to 28 mm in lesion length) of a native coronary artery of 2.0 mm to 2.5 mm in diameter (small coronary arteries), for the purpose of improving lumen diameter.

3. The balloon dilation of the stenotic portion (up to 18 mm in length) of an infrapopliteal artery (P-3 segment or distal, below the knee) with a reference vessel diameter (RVD) of 2.25 to 4.0 mm, for the purpose of improving lumen diameter.


Virtue® SAB is investigational and not commercially approved.

AVIM therapy is investigational and not commercially approved.